Inflammatory cell counts for subjects with neutrophilic, eosinophilic and paucigranulocytic asthma, bronchiectasis and controls
| Neutrophilic asthma | Eosinophilic asthma | Paucigranulocytic asthma | Bronchiectasis | Controls | p Value* | |
|---|---|---|---|---|---|---|
| Results are median (interquartile range). | ||||||
| *Kruskal–Wallis test p for five group analysis. | ||||||
| † p<0.0025 Kruskal–Wallis versus controls. | ||||||
| ‡p<0.0025 Kruskal–Wallis versus eosinophilic asthma. | ||||||
| §p<0.0025 Kruskal–Wallis versus paucigranulocytic asthma. | ||||||
| Total cell count, ×106/ml | 8.4 (6.6–9.7)†‡§ | 2.4 (1.0–4.4) | 1.4 (1–2.1) | 13.1 (3.9–22.2)†§ | 1.6 (0.8–2.4) | 0.0001 |
| Viability | 88 (87–97)†§ | 72 (59–80) | 50 (28–82) | 92 (67–96) | 60 (30–80) | 0.003 |
| Neutrophils, % | 79.8 (70.3–94.3)†‡§ | 29.1 (13.5–36) | 9.9 (6.3–25.9) | 65.3 (36.1–87.9)†§ | 13.9 (6.8–22.2) | 0.0001 |
| Neutrophils, 104/ml | 632 (589–816)†‡§ | 48.5 (30.7–104)§ | 13.1 (6.3–29.8) | 757 (153–1930)†§ | 16.9 (8.4–33.4) | 0.0001 |
| Eosinophils, % | 1 (0.3–1.75) | 3 (1.5–5) †§° | 0.13 (0–0.5) | 0.13 (0–0.8) | 0 (0–0) | 0.0001 |
| Eosinophils, 104/ml | 4.3 (1.6–14.3)†§ | 4.8 (1.6–25.7)†§ | 0.1 (0–0.8) | 0.4 (0–5.5) | 0 (0–0) | 0.0001 |
| Macrophages, % | 17.5 (5.5–26.2)†‡§ | 61.3 (46.8–75.8) | 77.2 (59.8–86.4) | 31.4 (11.8–53.5)†§ | 78 (66.9–86.4) | 0.0001 |
| Macrophages, 104/ml | 148 (36.1–175) | 102 (68.6–306) | 80.4 (58–123) | 490 (50.2–764) | 128 (63.1–200) | 0.151 |
| Lymphocytes, % | 0.3 (0–0.8) | 0.7 (0–1.5) | 0.7 (0–1.8) | 0.6 (0.3–1.1) | 0.6 (0–1.1) | 0.835 |
| Lymphocytes, 104/ml | 0.7 (0–6.4) | 1.1 (0–4.3) | 0.5 (0–1.9) | 5.5 (2.7–10) | 1.1 (0–3.1) | 0.162 |
| Columnar epithelial cells, % | 0 (0–0)†‡§ | 2.7 (1–7) | 6.6 (3.1–12.5) | 0 (0–6.5) | 3.6 (0.3–14.1) | 0.0006 |
| Columnar epithelial cells, 104/ml | 0 (0–0)‡§ | 4.7 (1.8–13.7) | 8.6 (5–13.9) | 0 (0–7.7) | 0.5 (0.4–16.4) | 0.002 |
| Squamous cells, % | 1.2 (0–5.2) | 1.7 (0.7–10.3) | 9.4 (4.9–16.8)‡ | 1.1 (0.4–6.8) | 8.9 (2.9–20.7) | 0.003 |